LAWRENCE, Mass., Oct. 18, 2018 /PRNewswire/ -- NxStage
Medical, Inc. (Nasdaq: NXTM), a leading medical technology company
focused on advancing renal care, announced new findings
demonstrating significant survival benefit and lower cardiovascular
hospitalization with more frequent home hemodialysis using the
NxStage® System One™ within the skilled nursing facility setting.
The data, developed in collaboration with Affiliated Dialysis
Centers, LLC, will be presented by NxStage at the American Society
of Nephrology (ASN) Kidney Week 2018 Annual Meeting on October 26th. Conference attendees can meet with
NxStage representatives at booth 1841 to discuss the recent
findings.
In a large study of 3,619 patients receiving hemodialysis in the
SNF setting between 2011-2015, patients receiving more frequent
home hemodialysis experienced 34% lower risk of death and 23% lower
risk of cardiovascular hospitalization, compared to patients
receiving conventional hemodialysis in a SNF setting.
"Because patients undergoing dialysis have a high burden of
cardiovascular disease, a 23% reduction in cardiovascular-related
hospitalization is very clinically meaningful," said Dr.
Maria Rosa Costanzo, Medical
Director, Heart Failure Research, Advocate Heart Institute. "These
findings are even more impressive in the high-risk population of
patients who reside in skilled nursing facilities."
"The significant survival and cardiovascular benefits associated
with more frequent on-site home hemodialysis provides confidence
and clear support for a new standard of care for dialysis patients
within skilled nursing facilities," said Allan Collins, Chief Medical Officer at NxStage
Medical. "Home hemodialysis provided in the skilled nursing
facility setting eliminates the needs and risks of high-cost and
disruptive transportation to and from dialysis clinics, and by
reducing hospitalization, more frequent on-site home hemodialysis
can provide better patient health outcomes at a lower cost of
care."
Dr. Eric Weinhandl, NxStage
clinical epidemiologist and lead author of the study, will present
these findings during an oral presentation at ASN on Friday, October 26th.
For more information about on-site home hemodialysis in Skilled
Nursing Facilities, visit www.nxstage.com/snf.
Despite the health benefits that home and more frequent
hemodialysis may provide to those with chronic kidney disease,
these forms of therapy are not for everyone. The reported benefits
of home hemodialysis may not be experienced by all patients. The
NxStage System is a prescription device and, like all medical
devices, involves some risks. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream, and blood
loss due to clotting or accidental disconnection of the blood
tubing set. When vascular access is exposed to more frequent use,
infection of the site, and other access related complications may
also be potential risks. Patients should consult with their doctor
to understand the risks and responsibilities of home and/or more
frequent hemodialysis using the NxStage System One. Patients and
providers are encouraged to contact their state regulators to
discuss state-specific regulations that may impact dialysis in the
Skilled Nursing Facility setting.
About the NxStage System One in the Skilled Nursing Facility
Setting
The NxStage System One is the first and only truly
portable hemodialysis system cleared specifically by the FDA for
home hemodialysis, including nocturnal and solo hemodialysis. The
System One provides individualized treatment options to meet the
clinical needs of SNF patients, which additionally may allow
patients to maintain rehabilitation, medication, meal and activity
schedules. Its simplicity and revolutionary size (just over a foot
tall) are intended to allow convenient use in the skilled nursing
facility (SNF) setting. www.nxstage.com.
About NxStage Medical
NxStage Medical, Inc. is a
leading medical technology company, headquartered in Lawrence, MA, USA, that develops,
manufactures, and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. For more
information on NxStage and its products and services, please visit
the Company's website at www.nxstage.com.
Forward-looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2018. NxStage
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: Kristen Sheppard,
ksheppard@nxstage.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/new-data-demonstrates-significant-survival-benefit-with-more-frequent-hemodialysis-using-the-nxstage-system-one-in-skilled-nursing-facility-setting-300733030.html
SOURCE NxStage Medical, Inc.